Matinas BioPharma Holdings, Inc. announced the U.S. Food and Drug Administration (FDA) has conditionally accepted LYPDISO™ as the proposed brand name for MAT9001, the Company’s investigational drug for treatment of cardiovascular and metabolic conditions. The company also announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance, approving the Company’s application to register the LYPDISO brand name as a federal trademark. The name LYPDISO (pronounced “Lip-DEE-so”) was developed in compliance with FDA’s Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names. Based on the development program, which included research with physicians and pharmacists, as well as an international name assessment, the Company believes LYPDISO is a proprietary name with strong marketing potential that is also consistent with FDA’s goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use. A request for proprietary name review and final approval for LYPDISO will be included when Matinas submits a New Drug Application (NDA) for MAT9001.